Focus is on Q1, but with much cash in hands of big pharma, I believe that a take out offer would get the technology on the cheap and into hands that would exploit the current marketing failure. Obviously, VRS has not mastered the art of lobbying, as demonstrated by the silence from the FDA approval process. Big pharma would solve this issue as well. My concern is that  Big pharma will get the whole enterprise for less than $1 per share.